Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 4/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31720801 | 1.00 | ACMSD (0.41) | ACMSDCDC7MRGPRX4PLA2G2AADORA2B | |
| SCHEMBL19206697 | 0.91 | MAPT (0.39) | ACMSDCDC7MAPTKMT2ANPC1 | |
| SCHEMBL19206672 | 0.89 | CDC7 (0.38) | CDC7MAPTHTT | |
| SCHEMBL492636 | 0.88 | LTB4R (0.41) | CDC7MAPTRAB9ASMN1; SMN2CA1 | |
| SCHEMBL19206714 | 0.88 | ALDH1A1 (0.38) | CDC7MAPTKMT2APARP1 | |
| SCHEMBL20211740 | 0.87 | KEAP1 (0.39) | ACMSDPLA2G2AADORA2BMAPTKMT2A | |
| SCHEMBL30800214 | 0.87 | KEAP1 (0.39) | ACMSDPLA2G2AADORA2BMAPTKMT2A | |
| SCHEMBL19206676 | 0.87 | LTB4R (0.38) | CDC7MAPTCA1CA2CA9 | |
| SCHEMBL20543423 | 0.86 | PDE3B (0.38) | CDC7ADORA2BMAPTNPC1RAB9A | |
| SCHEMBL20543611 | 0.86 | THRB (0.42) | CDC7MAPTKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORP (US) | 2025-11-06 | — | — | US | claimed |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2021-08-19 | — | — | US | claimed |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2021-05-25 | — | — | US | claimed |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-08-20 | — | — | US | claimed |
| US-10308975-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2019-06-04 | — | — | US | claimed |
| EP-3416968-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2018-12-26 | — | — | EP | claimed |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | claimed |
| WO-2017142852-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2017-08-24 | — | — | WO | claimed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | claimed |
| US-12391973-B2 | Substituted imidazo[1,2-α]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2025-08-19 | — | — | US | disclosed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-10308975-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3416968-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-9924073-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates and preparation method thereof | PROMEGA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| WO-2017142852-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2017-08-24 | — | — | WO | disclosed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | CYP4Z1, CYP2E1, CYP2F1 | ACMSD 525/4885CDC7 1157/4885MRGPRX4 2313/4885 |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | ACMSD 129/4885CDC7 919/4885MRGPRX4 2651/4885 |
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | ACMSD 665/4885CDC7 1805/4885MRGPRX4 3256/4885 |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | GLB1, PGLS, AADAC | ACMSD 697/4885CDC7 1738/4885MRGPRX4 2605/4885 |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | ACMSD 1759/4885CDC7 1299/4885MRGPRX4 1182/4885 |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | ACMSD 1759/4885CDC7 1299/4885MRGPRX4 1182/4885 |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | ACMSD 129/4885CDC7 919/4885MRGPRX4 2651/4885 |
| US-10308975-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | AADAC, PGLS, GLB1 | ACMSD 637/4885CDC7 1675/4885MRGPRX4 3190/4885 |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | ACMSD 665/4885CDC7 1805/4885MRGPRX4 3256/4885 |
| US-12391973-B2 | Substituted imidazo[1,2-α]pyrazines as luciferase substrates | PGLS, GLB1, AADAC | ACMSD 664/4885CDC7 1601/4885MRGPRX4 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.